|
KR20200035359A
|
|
Synthesis of novel intermediate(s) for preparing rivastigmine
|
|
US2018042850A1
|
|
Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity
|
|
JP2017101065A
|
|
Cancer antigen
|
|
WO2015008202A1
|
|
Indole-3-carbinol derivatives
|
|
EP2824103A1
|
|
An improved process for the preparation of Rupatadine Fumarate
|
|
WO2014111903A2
|
|
A process for the preparation of 6-fluoro-3,4-dihydro-2h-chromene- 2-carbaldehyde
|
|
CN105683185A
|
|
Novel piperidinyl benzoimidazole derivatives as mpges-1 inhibitors
|
|
WO2013186706A1
|
|
Process for the preparation of bosentan
|
|
AU2012279923A1
|
|
Cancer antigen
|
|
CA2828401A1
|
|
Therapeutic cancer vaccine
|
|
AU2012206322A1
|
|
Pharmaceutical composition for treating cancer
|
|
WO2012070025A1
|
|
Process for the preparation of agomelatine
|
|
WO2012069989A1
|
|
Process for preparation of clevidipine and its intermediate
|
|
WO2012063182A1
|
|
Pharmaceutical composition of taxoids
|
|
EP2616053A2
|
|
Pharmaceutical compositions of curcumin
|
|
WO2012017391A2
|
|
Novel compounds as dpp-iv inhibitors and process for preparation thereof
|
|
WO2011125011A1
|
|
Novel hypoglycemic compounds
|
|
WO2011101816A1
|
|
An improved process for the preparation of amorphous atorvastatin calcium
|
|
EA027915B1
|
|
Method of preparing a composition of killed cells with substantially retained immunogenicity
|
|
AP201206119A0
|
|
Pharmaceutical composition of isoniazid.
|
